These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30234232)

  • 1. [Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches].
    De Stefano T; Borrelli S; Garofalo C; Provenzano M; De Nicola L; Minutolo R; Conte G
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperkalemia - current therapuetic strategies].
    Głogowski T; Wojtaszek E
    Wiad Lek; 2016; 69(5):745-748. PubMed ID: 28033600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence in support of hyperkalaemia management strategies: A systematic literature review.
    Palaka E; Leonard S; Buchanan-Hughes A; Bobrowska A; Langford B; Grandy S
    Int J Clin Pract; 2018 Feb; 72(2):. PubMed ID: 29381246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New potassium binders effective: treatment of hyperkalaemia secondary to RAAS inhibitors].
    Hoorn EJ
    Ned Tijdschr Geneeskd; 2015; 159():A8801. PubMed ID: 25761299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.
    Georgianos PI; Liampas I; Kyriakou A; Vaios V; Raptis V; Savvidis N; Sioulis A; Liakopoulos V; Balaskas EV; Zebekakis PE
    Int Urol Nephrol; 2017 Dec; 49(12):2217-2221. PubMed ID: 29027620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
    Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
    J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potassium binding for conservative and preservative management of chronic kidney disease.
    Clegg DJ; Palmer BF
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):29-38. PubMed ID: 31714287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the management of hyperkalemia in chronic kidney disease.
    Cowan AC; Gharib EG; Weir MA
    Curr Opin Nephrol Hypertens; 2017 May; 26(3):235-239. PubMed ID: 28212180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches to management of hyperkalaemia in kidney transplantation.
    Rizk J; Quan D; Gabardi S; Rizk Y; Kalantar-Zadeh K
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):27-37. PubMed ID: 33027094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperkalemia: something old, something new.
    Sterns RH; Grieff M; Bernstein PL
    Kidney Int; 2016 Mar; 89(3):546-54. PubMed ID: 26880451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.